Launch of a broad public debate on the future of pharmaceuticals for human use in Europe

EUThe Commission launches a public consultation on the future of pharmaceuticals for human use in Europe. The pharmaceutical sector has been and remains a key strategic sector in Europe. The future of this sector is a crucial matter for the EU.

The Commission intends to improve the regulatory, non-regulatory and RTD framework for pharmaceuticals. For example, specific initiatives in the field of pharmacovigilance and variations have already been announced.

Contribution from all stakeholders -Patients organisations, Member States authorities, international bodies, industry associations and individual companies -innovative, generic and self-medication sectors-, healthcare professionals, or any other person or legal entity interested in this field- are welcome.

Stakeholders who are not established within the EU are equally invited to comment.

Comments from Small and Medium-sized Enterprises (SMEs) involved in the pharmaceutical sector are especially welcomed.

Contributions should preferably not exceed 5 pages.

KEY QUESTIONS

  • Do you agree with the analysis of the main challenges outlined above? Do you see other challenges?
  • Do you see other areas than those already targeted by the Commission where regulatory action should be taken?
  • What would you suggest as concrete measures to ensure the safety of medicines supplied in the EU, addressing in particular counterfeit medicines, and provision of high quality and affordable medicines also to third countries?
  • What can be done to improve Europe’s international competitiveness?
  • What can be done to foster convergence and transparency as regards pricing and reimbursement in the EU?
  • Do you think the current EU regulatory framework can accommodate emerging technologies like regenerative and personalised medicine, as well as nanobiotechnology?

Deadline to contribute: 12 October 2007

For futher information, please download (.pdf, 28 KB) Public Consultation: The future of pharmaceuticals for Human

Related news article:

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...